Effects of Surgical and Medical Treatment on Quality of Life for Patients With Chronic Thromboembolic Pulmonary Hypertension

Pulmonary Endarterectomy and Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension ― Similar Effects on Health-Related Quality of Life ―

“…Urushibara et al reported that longer 6MWD and lower PVR were associated with higher HRQOL score in treatment-naïve patients. 18 Moreover, in the same study, a surgically treated group had better improvements in HRQOL than a medically treated group. 18 Furthermore, Darocha et al reported that HRQOL was improved by BPA.…”

“…18 Moreover, in the same study, a surgically treated group had better improvements in HRQOL than a medically treated group. 18 Furthermore, Darocha et al reported that HRQOL was improved by BPA. 19 We previously identified early introduction of invasive therapies as a factor affecting final HRQOL.…”

“…There are several studies in which 6MWD and PVR were associated with HRQOL scores in patients with PAH or CTEPH. 17,18 In this study, we analyzed the correlation between HRQOL scores and clinical parameters before and after invasive therapy in order to investigate whether association between HRQOL score and clinical parameters was altered by invasive therapy. Before invasive therapy, BNP, mPAP, SaO2, and 6MWD had correlations with HRQOL scores.…”

Improvement in Quality of Life and Hemodynamics in Chronic Thromboembolic Pulmonary Hypertension Treated With Balloon Pulmonary Angioplasty

“…4,7,23,24 analysis of 128 CTEPH patients treated with PEA or medical therapy. 23 Changes in QoL was also assessed in the landmark BENEFiT study, which compared, in a randomized, double-blind trial, the effect of bosentan vs. placebo in 157 patients with inoperable CTEPH or persistent CTEPH after PEA. No significant change in QoL on SF-36 questionnaire was found in the bosentan group compared with the placebo group.…”

Adherence and medication belief in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A nationwide population‐based cohort survey

“…Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are rare diseases with a gradual decline in physical health as well as a varying psychological health, individually and over time, leading to poor quality of life . Unless undergoing double lung transplantation, there is no cure for PAH and the disease‐specific treatment aims to prolong life and increase the patients' quality of life by means of symptom relief and delayed disease progression . PAH‐targeted therapies include oral, inhaled, subcutaneous and intravenous drugs in addition to conventional supportive medical therapies.…”